News & Updates
Filter by Specialty:
Is laparoscopic better than open partial nephrectomy for renal tumours?
Patients with renal tumours who have undergone laparoscopic partial nephrectomy (LPN) have shown similar surgical and oncologic outcomes as those treated with open partial nephrectomy (OPN), reports a study.
Is laparoscopic better than open partial nephrectomy for renal tumours?
17 Jul 2022Hospitalization for COVID-19 shorter with dexamethasone vs methylprednisolone
In the treatment of COVID-19 inpatients, intravenous administration of dexamethasone leads to a shorter hospital stay compared with methylprednisolone, according to a study.
Hospitalization for COVID-19 shorter with dexamethasone vs methylprednisolone
17 Jul 2022Serum CTRP4 tied to coronary artery disease in T2DM
In patients with type 2 diabetes mellitus (T2DM), higher serum levels of circulating C1q tumour necrosis factor-related protein 4 (CTRP4) appear to aggravate the likelihood of coronary artery disease, a recent study has found.
Serum CTRP4 tied to coronary artery disease in T2DM
17 Jul 2022Mood, anxiety disorders may prolong hospital stay following radical cystectomy
For bladder cancer patients scheduled to undergo radical cystectomy, the presence of mood and/or anxiety disorders may lead to a longer length of hospital stay and increase the likelihood of discharge to a nonhome facility, a study reports.
Mood, anxiety disorders may prolong hospital stay following radical cystectomy
16 Jul 2022Cetuximab plus chemoradiotherapy feasible in women with cervical carcinoma
Treatment with cetuximab plus cisplatin 30 mg/m2 and radiotherapy appears safe and well tolerated in women with cervical carcinoma, a study has shown. In addition, fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) has exhibited early evidence of response to neoadjuvant cetuximab.
Cetuximab plus chemoradiotherapy feasible in women with cervical carcinoma
16 Jul 2022Upfront ASCT + RVd improves PFS in NDMM
Upfront autologous stem cell transplantation (ASCT) plus lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), results of the phase III DETERMINATION trial showed.